Dopaminergic ligands to treat tissue fibrosis
Idiopathic pulmonary fibrosis is a rare fatal disease with no cure. The mechanism of this disease is unknown. Mayo Clinic is working on identifying this mechanism and has identified an specific target: the Dopamine D1 receptors. Cell selective dopamine D1 receptor agonists are under development for the treatment of this disease.